Search
Search
ASRS: 2022
Lloyd Clark, MD, FASRS
Show Description +
Lloyd Clark, MD, FASRS, discusses promising results of a phase 2 trial evaluating 8 mg aflibercept compared with the FDA-approved 2 mg dose (Eylea, Regeneron) for wet AMD.
Posted: 7/20/2022
Lloyd Clark, MD, FASRS
Lloyd Clark, MD, FASRS, discusses promising results of a phase 2 trial evaluating 8 mg aflibercept compared with the FDA-approved 2 mg dose (Eylea, Regeneron) for wet AMD.
Posted: 7/20/2022
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2022.
Please log in to leave a comment.